소아골수단핵구백혈병의 분자생물학적 이해
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 전인상 | - |
dc.date.available | 2020-02-27T15:41:17Z | - |
dc.date.created | 2020-02-12 | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 2233-5250 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/5064 | - |
dc.description.abstract | To date, hematopoietic stem cell transplantation (HSCT) is the only choice of therapy for most patients with juvenile myelomonocytic leukemia (JMML). Relapse remains a major problem. Approximately 90% of patients carry either somatic or germline mutations of genes participating in RAS signal transduction such as PTPN11, CBL, K-RAS, N-RAS, or NF1 in their leukemic cells, allowing an understanding of the molecular pathophysiology of JMLL and the development of novel drugs. As these genetic aberrations are mutually exclusive, the genetic change observed in JMML helps us to establish the diagnosis of JMML. Furthermore, the genetic abnormalities of JMML are an important prognostic factor, as the type of abnormality may determine disease progression. Recent studies have revealed a strong association between hypermethylation of some genes and already known poor prognostic factors such as older age, elevated fetal hemoglobin at diagnosis, and somatic mutation of PTPN11. These molecular characteristics may be the basis for a guideline to determine the treatment, especially when to proceed with HSCT. Recently, novel drugs have been used based on these molecular characteristics. 5-Azacitidine, an inhibitor of DNA methyltransferase and tipifarnib, a selective farnesyl transferase inhibitor, have been used to improve the outcome of JMML. In addition, drugs which inhibit the RAS signal transduction have been developed, which are less toxic and will improve outcome in the near future. | - |
dc.language | 한국어 | - |
dc.language.iso | ko | - |
dc.publisher | 대한소아혈액종양학회 | - |
dc.relation.isPartOf | Clinical Pediatric Hematology-Oncology | - |
dc.title | 소아골수단핵구백혈병의 분자생물학적 이해 | - |
dc.title.alternative | Understanding the Molecular Basis of Juvenile Myelomonocytic Leukemia and Its Application for Novel Drugs Development | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 2 | - |
dc.identifier.doi | 10.15264/cpho.2018.25.1.23 | - |
dc.identifier.bibliographicCitation | Clinical Pediatric Hematology-Oncology, v.25, no.1, pp.23 - 30 | - |
dc.identifier.kciid | ART002339720 | - |
dc.citation.endPage | 30 | - |
dc.citation.startPage | 23 | - |
dc.citation.title | Clinical Pediatric Hematology-Oncology | - |
dc.citation.volume | 25 | - |
dc.citation.number | 1 | - |
dc.contributor.affiliatedAuthor | 전인상 | - |
dc.subject.keywordAuthor | Juvenile myelomonocytic leukemia (JMML) | - |
dc.subject.keywordAuthor | RAS pathway | - |
dc.subject.keywordAuthor | 5-Azacitidine | - |
dc.subject.keywordAuthor | Tipifarnib | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.